|Bid||1.52 x 1000|
|Ask||1.55 x 1100|
|Day's Range||1.40 - 1.55|
|52 Week Range||1.32 - 25.60|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.75|
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 39 cents. The company's shares closed at $1.79. A year ago, they were trading at $7.92. _____ This story was generated by ...
GTx, Inc. today reported financial results for the third quarter ended September 30, 2018, and provided a corporate update.
The more than 50 current and former executives at Memphis-based public companies earned $180 million in total compensation in 2017.
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / October 8, 2018 / GTx Inc. was seeing big gains on Friday despite any news. The company had recently saw its shares collapse on news that its only drug candidate had failed a mid-stage clinical trial. Shares of TrovaGene Inc. were also in the green despite any news on Friday, but it was last week that the company announced it had entered into an exclusive patent license agreement with the Massachusetts Institute of Technology.
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Shares of GTx were deep in the red on Friday on disappointing news that the company’s only drug candidate had filed a mid-stage clinical trial. Shares of Protalix BioTherapeutics on the other hand were soaring on positive preliminary data. GTx, Inc. shares closed down a little over 92% on Friday, making it one of the biggest decliners on the Nasdaq.
The company's only drug candidate failed a mid-stage clinical trial. The next clinic-ready assets are on the way -- in late 2019 or early 2020.
GTx Inc. stock dropped as much as 94% in Friday premarket trade after the company said that enobosarm, its therapy intended for post-menopausal women with stress urinary incontinence, did not meet the primary endpoint in a phase 2 clinical trial. The double-blind and placebo-controlled trial had enrolled nearly 500 women. Enobosarm is the company's main product candidate, which it has been developing in stress urinary incontinence as well as breast cancer. GTx is also developing a preclinical candidate for prostate cancer. Company shares have surged nearly 26% to $23.29 over the last three months, compared with a 6.6% rise in the S&P 500 and a nearly 9% rise in the Dow Jones Industrial Average .
GTx, Inc. (GTXI) today announced that the ASTRID Trial, a Phase 2 double-blind, placebo-controlled clinical trial of orally-administered enobosarm (3 mg or 1 mg) in post-menopausal women with stress urinary incontinence (SUI), did not achieve statistical significance on the primary endpoint of the proportion of patients with a greater than 50% reduction in incontinence episodes per day compared to placebo. “We are very disappointed that the ASTRID Trial did not achieve its primary endpoint,” said Robert J. Wills, Ph.D., Executive Chairman of GTx.
GTx, Inc. today announced that Robert J. Wills, PhD, Executive Chairman, and other senior executive management team members will present a company overview at the Baird 2018 Global Healthcare Conference on Thursday, September 6, 2018 at 9:05 am ET in New York.
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ferroglobe ...
On a per-share basis, the Memphis, Tennessee-based company said it had a loss of 43 cents. GTx shares have increased 40 percent since the beginning of the year. The stock has more than tripled in the last ...
-- Completed patient enrollment in the ASTRID Trial, a Phase 2 double-blinded, placebo-controlled clinical trial of enobosarm in Stress Urinary Incontinence --
This was a multicenter, randomized, double blind, placebo controlled trial that enrolled a total of 108 subjects (83 women and 25 men) age ≥ 65 years of age who had suffered a hip fracture within the past three to seven weeks. Subjects were administered placebo or 0.5 mg, 1.0 mg, or 2.0 mg of VK5211 once-daily for 12 weeks (NCT02578095). The primary outcome of the trial was the change in lean body mass, less head, after 12 weeks of treatment.
GTx, Inc. today announced that it has been added to the Russell 3000® Index as part of the Russell U.S. Indexes annual reconstitution. The addition will take effect after the U.S.
GTx, Inc. today announced that Robert J. Wills, PhD, Executive Chairman, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 10:00 am ET in New York.
GTx, Inc. (GTXI) today released additional data supporting the durability of the response to a 12-week treatment with enobosarm 3 mg in an open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm in postmenopausal women with stress urinary incontinence (SUI). The presentation, entitled Oral Enobosarm Shows Promising Activity in Post-Menopausal Women with Stress Urinary Incontinence: Results of a Phase 2 Study, took place at the 2018 American Urological Association annual meeting being held in San Francisco, CA, from May 18 to 21, 2018. “The overall treatment effect of enobosarm in this proof-of-concept trial demonstrates the potential of enobosarm to effectively treat SUI, the most common type of incontinence suffered by women,” said Kenneth M. Peters, M.D., Chairman of Urology, Oakland University William Beaumont School of Medicine, and the principal investigator in the trial.